Infectious Disease Programs: Celldex has several programs with significant potential for preventing or treating infectious diseases. Although these programs are not currently sponsored by the Company, there is significant enthusiasm to apply the Precision Targeted Immunotherapy platform to this field in the future.
- DCVax-001 – HIV Vaccine: Celldex and Rockefeller University investigators are collaborating on an effort to develop a vaccine against HIV, the virus known to cause AIDS. The Rockefeller vaccine, called DCVax-001, is an APC-targeted vaccine consisting of a fusion protein of a human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program has been funded through a grant from the Bill & Melinda Gates Foundation. The vaccine is currently being tested in a Phase 1 trial in healthy volunteers at Rockefeller University. For citations related to DCVax-001 click here.